The aim of this multicentre, randomized study was to compare the ecacy and safety of moxi¯oxacin (BAY 12-8039), a new 8-methoxy¯uoroquinolone, with that of cefuroxime axetil for the treatment of acute bacterial sinusitis in adults. Diagnosis was made on a range of clinical signs and symptoms combined with radiology and microbiology.
Introduction
Acute bacterial sinusitis is a common infection of one or more of the paranasal sinuses. It frequently occurs as a complication of a cold or other viral infection of the upper respiratory tract (1, 2, 3) . Repeated episodes of acute sinusitis in untreated or inadequately treated patients can lead to irreversible changes and chronic sinusitis. Early diagnosis and eective antimicrobial therapy is thought to be important for the prevention of such complications (2, 4) . Accurate diagnosis based on clinical grounds can be dicult and needs to be combined with techniques such as radiography, ultrasonography or computer tomography and by microbiological culture (4, 5, 6) . Common symptoms are post-nasal purulent discharge, facial pain, hyposmia, jaw pain and nasal congestion (4, 6, 7) Streptococcus pneumoniae and Haemophilus in¯uenzae usually account for at least 50% of bacterial pathogens in patients with acute bacterial sinusitis (1, 5, 7, 8) . Staphylococcus aureus, Moraxella catarrhalis and Streptococcus pyogenes can also be important but less frequent pathogens. Anaerobic and Gram-negative organisms are more rarely involved (2, 7, 8) .
Empiric therapy with penicillins has been the standard for many years. However, the increasing frequency of blactamase-producing strains of H. in¯uenzae, S. aureus and M. catarrhalis and the spread of strains of S. pneumoniae with reduced susceptibility to penicillins (1,9±11) has led to the use of a wider range of antibacterial agents to combat this reduction in sensitivity. Resistance to macrolides has also increased in recent years, reducing the therapeutic options for respiratory tract infections (9, 10) . Ideally the therapeutic agent should be eective against the more commonly occurring organisms. Many current agents need to be administered more than once a day, usually for 10 days, and this can lead to problems with compliance (12, 13) .
Moxi¯oxacin (BAY 12-8039) is a new 8-methoxy¯uor-oquinolone, developed by Bayer AG in Wuppertal and Leverkusen, Germany. It shows improved activity against Gram-positive organisms compared with earlier¯uoroqui-nolones, whilst retaining activity against Gram-negative organisms (14, 15) . The compound is a pure enantiomer and is chemically stable. Moxi¯oxacin shows advantages in activity against a number of important species of Grampositive bacteria in vitro compared with other¯uoroquino-lones, including o¯oxacin, levo¯oxacin and spar¯oxacin, and is similar in activity to cipro¯oxacin against Gramnegative organisms, with the exception of Pseudomonas aeruginosa (15, 16) . There are indications that Grampositive organisms are less prone to acquire resistance against moxi¯oxacin than against older¯uoroquinolones (16) .
Moxi¯oxacin is well absorbed orally, with a long half-life and high volume of distribution (17) and recent studies have shown that it has particularly good activity against S. pneumoniae, H. in¯uenzae and M. catarrhalis, organisms important in respiratory and sinus infections (18) . Moxioxacin may thus represent a signi®cant improvement over currently available oral antibiotics, including b-lactams, macrolides and other¯uoroquinolones. Its broad spectrum of activity in vitro, including activity against drug-resistant pathogens, should prove valuable, especially for empirically-based treatment regimens (14, 16) . This would include infections of the respiratory tract which are caused by the community-acquired pathogens referred to above. In addition, moxi¯oxacin has activity against other respiratory pathogens such as Chlamydia, Legionella and Mycoplasma species (14, 15) .
Cefuroxime-axetil was chosen as the control in this study because of its known activity against the pathogens most commonly found in acute bacterial sinus infections, its high stability against various b-lactamases and its general acceptance by the medical community as a therapy for sinusitis (19) .
Materials and methods

STUDY DESIGN
This was a prospective, randomized, double-blind, Phase III clinical trial carried out in 60 centres in seven countries. The safety and ecacy of moxi¯oxacin, at a dose of 400 mg once daily for 7 days was compared with that of cefuroxime axetil, at a dose of 250 mg twice daily for 10 days, in the treatment of adult patients with acute bacterial sinusitis. The study protocol was prepared in accordance with the European Guide for Good Clinical Practice and national and regional regulations, and was reviewed by all appropriate national and regional ethical committees.
PATIENTS
The subjects were outpatient adults of either sex, aged 18 or over, with acute bacterial sinusitis. Sinusitis was diagnosed either bacteriologically or clinically on the basis of radiological paranasal sinus X-ray together with two or more of the following symptoms; nasal congestion, postnasal drainage, frequent coughing or throat clearing, frontal headache, malar tenderness or pain and purulent nasal discharge.
Females of child-bearing age had to be using a reliable contraceptive method. Subjects with a history of hypersensitivity to either of the study drugs or related compounds were excluded, as were those who had received any systemic antibacterial therapy within 48 h of enrolment, or those requiring concomitant systemic antibacterial treatment. Subjects with a history of chronic sinusitis or previous sinus surgery, or with two or more documented acute sinusitis episodes within the previous 6 months were excluded. Other exclusion criteria included neutropenia, liver disease or renal insuciency, AIDS, any severe infection or severe cardiac failure, a history of tendinopathy with¯uoroquinolones and pregnancy or lactation in women. Written informed consent was obtained from all patients prior to inclusion.
Details of all concomitant medications (mostly nasal decongestants or mucolytic drugs) were recorded. Systemic or topical corticosteroid administration was not allowed during the study. Antacids were only allowed up to 2 h prior to and after 4 h following drug intake.
TREATMENT
A total of 498 patients were recruited from centres in Finland, France, Germany, Greece, Israel, Spain and Sweden, 493 of whom were randomized to receive treatment. Moxi¯oxacin was administered as a 400 mg capsule each morning and a placebo capsule in the evening for 7 days to 242 patients. To ensure blinding, the patients in the moxi¯oxacin group received two placebo capsules from days 8±10. Cefuroxime axetil was administered to 251 patients as two daily capsules of 250 mg for 10 days. Compounds were taken orally with meals and 100 ml water.
EVALUATION
A full medical history was obtained before inclusion, and the patients were examined clinically and an occipitomental X-ray taken (Waters' view). Sinus radiographs were graded according to the degree of mucoperiosteal thickening, opaci®cation and air¯uid levels. A blood and urine sample was collected for analysis and haematology. Samples were collected for microbiological examination using three dierent methods according to the preference of the investigators. These were either a swab, collected under endoscopic view, cannulation of the middle meatus or a sinus puncture. Sinus puncture or aspiration was used by most Scandinavian investigators, but also by some in Germany, Southern Europe and Israel. Cannulation was used in France, and swabs by a number of investigators in Germany, Southern Europe and Israel.
A clinical assessment of progress was made and samples of blood and urine collected between 7±9 days of treatment, an end of treatment examination was made on day 14, and a follow-up evaluation was made 27±31 days after the end of treatment. Wherever possible, samples were collected for microbiological examination again at the end of treatment visit, and if patients had relapsed, again at the follow-up visit. An additional X-ray at the end of treatment was optional.
Overall clinical response was categorized as`resolution', improvement',`failure' or`indeterminate', based on scoring the signs and symptoms as`none',`mild',`moderate' or severe'. The clinical response was the primary ecacy evaluation and the bacteriological response was a secondary end-point. Cultures collected before and after therapy were used to assess response as`eradication' where the causative organism was not present at the end of therapy and the patient was improved clinically. If no sample was obtained in patients who had improved, eradication was presumed'.`Persistence' was where the causative organism was still present at the end of therapy, and`presumed persistence' was where no sample was available and the patient had not improved clinically. The presence of a dierent pathogen during therapy or immediately after therapy together with signs and symptoms of infection requiring treatment with another antibacterial agent was regarded as`superinfection'. Any non-evaluable response was termed`indeterminate'.
Any adverse event was recorded, using COSTART terms and de®nitions, and the patient observed closely until the event had resolved or the patient's condition had become normal. Safety analysis was performed on all patients who had received at least one dose of the study drug. The incidence and severity of adverse events was noted and their relationship to the drug administered assessed in accordance with CIOMS III/ICH-4 as none, possible, probable or not assessable.
STATISTICAL EVALUATION
The primary ecacy variable was the clinical response in the patients completing therapy (evaluable population) and the response in the two treatment groups was compared by calculating a two-sided 95% con®dence interval for the dierence using Mantel±Haenszel weighting. A dierence of more than 15% in the lower limit was required to prove that moxi¯oxacin was no less eective than the comparator.
Results
BASELINE CHARACTERISTICS
The demographic and clinical characteristics, including the presence of the six pre-speci®ed clinical signs and symptoms, at baseline in both groups of the intent-to-treat (ITT) population are listed in Table 1 . The groups were well balanced, with no major dierences being seen. Slightly more patients were assessed as having a severe infection and fewer a moderate infection at baseline in the moxi¯oxacin group, than in the cefuroxime axetil group (P=0Á07). Slightly more patients in the cefuroxime axetil group had a history of other diseases in addition to the sinusitis (50Á6% vs. 44Á2%, P=0Á16).
CLINICAL EVALUATION
Numbers evaluable for clinical ecacy were 211 of the 242 patients in the moxi¯oxacin group and 225 of the 251 in the cefuroxime axetil group. The reasons for non-evaluability did not dier signi®cantly between the groups, and the main reasons were insucient duration of therapy (21), violation of inclusion or exclusion criteria (18) and essential data missing (14) .
The clinical responses at the end of treatment (day 14) in both the ITT and evaluable groups are detailed in Table 2 . There was complete resolution of clinical symptoms in 89% of the moxi¯oxacin group and 87% of the cefuroxime axetil group in the ITT population, and in 96Á7% and 90Á7% respectively in the evaluable population. The 95% con®dence intervals (1Á5%; 10Á6%) indicate that moxi¯oxacin was not only as good as, but more eective than cefuroxime axetil. Results at the follow-up of the clinical successes 21± 28 days after the end of therapy are detailed in Table 3 , and showed that 90Á7% of patients treated with moxi¯oxacin and 89Á2% of those treated with cefuroxime axetil were still assessed as successes. The number of relapses and patients lost to follow-up were similar in each group. The 95% con®dence intervals were 74Á3%; 5Á4%, indicating no signi®cant dierence between the treatments.
MICROBIOLOGICAL EVALUATION
Cultures deemed to be pathogenic or`causative' were isolated from 257 of the 493 patients (52Á1%) at baseline and 224 of these were deemed to be evaluable for microbiological ecacy (45Á4%), 109 in the moxi¯oxacin group and 115 in the cefuroxime axetil group. In the majority of patients (202/257 or 78Á6%) only one pathogen was cultured, but in 46 patients (17Á9%) there were two pathogens and in nine patients (3Á5%) there were three pathogens isolated. The predominant causative organisms were S. pneumoniae (96), H. in¯uenzae (76), S. aureus (26) and M. catarrhalis (25) . Cannulation proved to be the most eective method of obtaining positive bacterial cultures, and swabs the least eective method, but these dierences were small.
The bacteriological success and failure rates are detailed in Table 4 . Bacterial success was taken as a combination of eradication and presumed eradication and was high in both groups. There were only six failures in the moxi¯oxacin group and 19 in the cefuroxime axetil group. Failures included those patients in whom the original infecting organism was eradicated, but which was replaced by another pathogen (superinfection). The 95% con®dence intervals indicated a signi®cant dierence, with moxi¯ox-acin being better than cefuroxime axetil. The clinical assessment of these patients who were evaluable microbiologically showed a higher success rate for the moxioxacin group, 103/109 (94Á5%) compared with 96/115 (83Á5%) in the cefuroxime axetil group.
The details of the eradication or persistence of the four major pathogens is given in Table 5 . Three patients receiving cefuroxime axetil had a persistent S. pneumoniae infection and ®ve patients a persistent H. in¯uenzae infection. The corresponding numbers for patients treated with moxi¯oxacin were only one of each. Other organisms not eradicated were one Proteus mirabilis and two Pseudomonas aeruginosa in the moxi¯oxacin group and one Staphylococcus epidermidis and two Streptococcus spp. in the cefuroxime axetil group. The median MIC values for each drug against the four species are also included in Table 5 . These values are for all strains isolated in the study, not just the organisms isolated from the evaluable patients. Cefuroxime axetil was less active than moxi¯ox-acin against all but the pneumococci. When persistent organisms were cultured at the end of treatment, they were still susceptible to the drug administered, with the exception of a strain of S. aureus where the MIC of cefuroxime axetil increased from 0Á5 mg l 71 pre-therapy to 4Á0 mg l 71 posttherapy.
SAFETY EVALUATION
All patients who received at least one dose of drug, that is the ITT population (n=493), were included in the safety assessment. Table 6 summarizes the total incidence of adverse events and indicates whether they were drugrelated, serious, and whether they led to treatment being discontinued. There were more patients with drug-related adverse events in the group receiving moxi¯oxacin (31% vs. 22%), but fewer of these drug-related events were serious (0% vs. 2%). These dierences were not statistically signi®cant. None of the serious events occurring in the moxi¯oxacin group were regarded as drug-related, whereas three serious events occurring in two patients treated with cefuroxime axetil were believed to be drug-related. There were a similar number of withdrawals because of an adverse event in both groups. The type of adverse events that were drug-related are listed in Table 7 . This includes probably and possibly drug-related events. The most common adverse event in each group was diarrhoea, with abdominal pain, nausea and vomiting being less frequent. All adverse events occurring in both groups resolved satisfactorily. Laboratory analysis of serum and urine samples showed no clinically related dierences between the two groups.
Discussion
Although some controversy exists over the necessity for treatment of acute bacterial sinusitis (20, 21) most would accept that when diagnosed properly, treatment should be given to prevent both the development of chronic sinusitis or rarer complications (4, 5, 21) . Considerable care was given in this study in the diagnosis of sinusitis. Distinguishing between acute sinusitis and rhinitis can be dicult, especially when using physical examination only (20) , but in this study ear, nose and throat (ENT) specialists were used who have greater experience than general practitioners in diagnosing this condition. In addition to several clinical signs and symptoms needing to be present, radiology was used and bacteriological sampling was performed. The single Waters' radiographical view was chosen; this is widely used because it is simple to perform and relatively cheap. It has been criticised by some as not being as sensitive a diagnostic tool as three or four view radiographs (22) or CT scans (23) . However, these and other studies do show that the Waters' view is a good diagnostic tool for the commonest form of sinusitis, namely maxillary sinusitis, comparing favourably with other methods, particularly when combined with other approaches and when used by ENT specialists, such as in this study (22±24).
Bacterial cultures were collected by three methods, cannulation, aspiration and swabs, depending on the local clinicians' practice. The numbers of patients with positive cultures were high for this type of study (450%) and this indicates both the accuracy of the diagnosis and the adequacy of the sampling technique. The predominant pathogens were S. pneumoniae and H. in¯uenzae, with the next most prevalent organisms being M. catarrhalis and S. aureus. This is in agreement with most studies on the aetiology of acute bacterial sinusitis (1, 5, 7, 8) .
This was a multicentre, randomized prospective trial in adults with acute bacterial sinusitis and was designed to compare the ecacy and safety of moxi¯oxacin with cefuroxime axetil. Cefuroxime axetil has been widely used in such infections as it has greater stability to b-lactamases than amoxycillin. Its use in sinusitis has been summarized by Pakes et al. (19) . A dose of 400 mg of moxi¯oxacin was given once daily for 7 days to 242 patients in contrast with a twice daily dose of 250 mg of cefuroxime axetil given to 251 patients for 10 days.
The statistical evaluation showed that the success rate in the evaluable patients at the end of treatment was signi®cantly higher for moxi¯oxacin (96Á7%) and the failure rate lower (3Á3%) than for cefuroxime axetil (90Á7% and 9Á3% respectively). The results at follow-up also showed that moxi¯oxacin was at least as eective as cefuroxime axetil. The bacteriological eradication rate was higher with moxi¯oxacin (94Á5%) than with cefuroxime axetil (83Á5%). An interesting point was the failure of cefuroxime axetil to eradicate three of the pneumococcal infections in spite of having lower MICs than moxi¯oxacin against these strains. Moxi¯oxacin has excellent penetration into cells and tissues, resulting in levels in excess of the MIC value at the site of infection, and this good penetration could account for the high rate of eradication of pneumococcal infections. A recent study by Andrews et al. (25) showed that following a single oral dose of 400 mg, moxi¯oxacin penetrated into the respiratory tree in high levels. Levels in alveolar macrophages remained above 10 mg l 71 for over 24 h post-dosing. In addition, Stass et al. (17) have shown that moxi¯oxacin penetrates into saliva with levels persisting for more than 24 h after a single dose.
The good tissue penetration of moxi¯oxacin resulting in high concentrations at the site of infection, may become increasingly important with the spread of antibioticresistant strains. Resistance to macrolides in pneumococci has increased in Europe in recent years more than in the U.S.A., and this has been associated with the increased use of macrolides in Europe (9) . Similarly, penicillin-resistance has been linked not just to penicillin use, but to overall use of b-lactams, and particularly to an increase in cephalosporin use (9) . There is also some evidence that low levels of b-lactams dosed for a long period can increase the possibility of the development of low-level resistance (26, 27) . In this context, there is much interest in the use of shorter courses of therapy (27) . In this study, a 7-day course was used rather than the more widely used 10-day course of therapy. Moxi¯oxacin, with its long half-life and good tissue penetration is eminently suitable for such a dosing regimen.
This study has shown that moxi¯oxacin compares favourably with cefuroxime axetil in the treatment of acute bacterial sinusitis in adults both in clinical and bacteriological ecacy and in safety. The simple once-daily, short course, dosing regimen oers advantages over many existing agents and can increase compliance. Good activity has been reported against a wide range of respiratory pathogens, including many with resistance to b-lactams and to other commonly used antibiotics. These factors indicate that moxi¯oxacin may have utility in a range of respiratory tract infections.
